Last updated 7 days ago
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
750 patients around the world
Available in Puerto Rico, Spain, United States, Argentina, Brazil
BeiGene
2Research sites
750Patients around the world
This study is for people with
Non-Hodgkin Lymphoma
Follicular lymphoma
Lymphoma
Marginal zone lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Histologically confirmed grade 1-3a FL or MZLPreviously received ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapyNeed for systemic therapy for FL or MZLMeasurable disease by computed tomography or magnetic resonance imagingAdequate bone marrow, liver and renal function
- Transformation to aggressive lymphomaRequiring ongoing need for corticosteroid treatmentClinically significant cardiovascular diseasePrior malignancy within the past 2 yearsActive fungal, bacterial, and/or viral infection that requires systemic therapy
Sites
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Hospital Alemán
Recruiting
StudyBGB-3111-308
SponsorBeiGene
Conditions
Follicular lymphomaMarginal zone lymphoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05100862
